BioSpace News Archive

The global scaffold technology market size was US$ 1,212.2 million in 2023 and is projected to surpass the market size of US$ 4,714.7 million by 2032, growing at a CAGR of 16.29% during the forecast period from 2024 to 2032.

Up to 86 percent of hospitalized patients with Alzheimer’s disease and related dementias have oropharyngeal dysphagia, a type of swallowing dysfunction that can lead to aspiration, pneumonia, malnutrition, intubation, and even death.

MicroGenDX, a global leader in next-generation sequencing diagnostics of infection, and members from the academic lab of Caleb Phillips at Texas Tech University will present four groundbreaking oral presentations at the Wound Healing Society meeting in May 2024.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company’s recent developments.

Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress, which takes place June 5-8, 2024 in Milan, Italy.

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.

Profound Medical Corp. is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia patients have been made at major medical meetings already in 2024.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced the conversion of an additional $15 million of its term loan with entities affiliated with CRG Servicing LLC into T2 Biosystems equity.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced unaudited financial and operational results for the first quarter ended March 31, 2024.